Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tobinick, Edward Lewis, M.D.
Etanercept, a biologic anti-TNF fusion protein, will be administered weekly or biweekly by perispinal injection to a maximum of 15 study subjects for a period of one month, followed by a 5 month and a 6 month possible study extension, with serial testing of cognition and function monthly.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
NINCDS-ADRDA Criteria for Alzheimer's disease
CT or MRI consistent with AD
You may not be if
active infection
CHF
demyelinating disease
uncontrolled diabetes mellitus
vascular dementia
clinically significant neurologic disease other than AD
Hachinski \>4
history of lymphoma
TBC
wbc\<2500
platelets\<100,000
HCT\<30
pregnancy
premenopausal, fertile not on acceptable birth control
change in neuroactive medication within 4 weeks of study initiation
